Lightpoint

An investigator-initiated trial supported by Lightpoint has highlighted the safety profile and early feasibility of using SENSEI® with a 99mTc-PSMA-targeted tracer for the intraoperative detection of metastatic lymph nodes in primary prostate cancer, prior to robot-assisted radical prostatectomy. Building on previous results for sentinel node biopsy, the publication demonstrates the utility of Lightpoint’s drop in gamma probe at initial diagnosis, potentially broadening the application of this technology in the disease, where radioguided surgery with this tracer has typically been performed in the recurrent setting. Further research is now being conducted to confirm the ability of SENSEI and targeted radiation imaging agents to detect micrometastatic prostate cancer during surgery as well as exploring their use in other urologic and non-urologic malignancies. Read the paper below or visit https://lnkd.in/dekia9t for more on Lightpoint and SENSEI

In a world first, SENSEI®, Telix’s miniature robotic-assisted gamma probe, has been used in a bladder cancer sentinel lymph node (SLN) procedure at Hospital del Mar in Barcelona, Spain. When used in tandem with a targeted radiation imaging agent, SENSEI® can potentially help surgeons find tumours during surgery and remove them with a high degree of precision. As we focus on aligning SENSEI® with our Illuccix® and TLX599-CDx programs for prostate cancer, this successful procedure demonstrates the potential and scope to expand use into other urologic malignancies – in line with Telix’s portfolio approach to support the patient from diagnosis to surgical intervention and therapy. To read more, click here: https://lnkd.in/gdE4DFqr #MedicalInnovation #BladderCancer #SENSEI SENSEI® has attained a marketing authorisation in the U.S and a Conformité Européenne (CE) Mark for use in the European Economic Area for the intra-operative detection of SLNs. With the exception of Illuccix® and SENSEI®, no Telix product has received a marketing authorisation in any jurisdiction.

When Andre’s doctor found a 3mm suspected prostate cancer nodule on his PSMA PET scan, he was told that surgically removing it would be like “finding a needle in a haystack” and that androgen deprivation therapy and radiation were the best options. Instead, thanks to a UCLA clinical trial of PSMA radioguided surgery using Lightpoint’s SENSEI gamma probe, Andre had the nodule successfully removed without the need for further treatment. Now, 17 months post-surgery, Andre’s latest PSA is less than 0.04, essentially undetectable. Read about more about Andre’s story here: https://lnkd.in/gA2HXgGW Lightpoint is a Telix Group company. SENSEI is approved for intra-operative detection of sentinel lymph nodes in the EU and US, in all other indications it is for investigational use only.